Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Neuroendocrine Carcinomas (NEC) · Neuroendocrine Carcinoma of Pancreas · Neuroendocrine Carcinoma of Prostate

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Asan Medical Center, Seoul, South Korea
Contact: Study coordinator (InKeun Park, M.D, Ph D) · ikpark@amc.seoul.kr · +82-3010-3266
Samsung Medical Center, Seoul, South Korea
Contact: Study coordinator (Sung Hee Lim, M.D, Ph D) · sunghee1022.lim@samsung.com
Seoul National University Hospital, Seoul, South Korea
Contact: Study coordinator (Jeonghwan Youk, M.D, Ph D) · jhyouk@snu.ac.kr
Yonsei Severance Hospital, Seoul, South Korea
Contact: Study coordinator (Sang Joon Shin, M.D, Ph D) · SSJ338@yuhs.ac

Study leads

Inkeun Park, M.D, Ph D
Principal Investigator
Asan Medical Center

View source on ClinicalTrials.gov Contact study team (email)